Expertise in
6
conditions

Nathalie Meuleman

Brussels, BRU, BE 
Expertise in
6
conditions
Brussels, BRU, BE 

Overview

Nathalie Meuleman practices practicing medicine in Brussels, Belgium.

Ms. Meuleman is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

She is actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Brussels, BRU, Belgium
Other Locations
Anderlecht, BRU, Belgium
Gosselies, WAL 6041, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 2
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

91 Total Publications

Belgian recommendations for tissue diagnosis of amyloidosis.
Belgian recommendations for tissue diagnosis of amyloidosis.
Journal: Acta clinica Belgica
Published: April 27, 2026

Frequently Asked Questions about Nathalie Meuleman

Is Nathalie Meuleman a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Nathalie Meuleman is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nathalie Meuleman participate in research or clinical trials?

Yes. Nathalie Meuleman has published 91 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Nathalie Meuleman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Meuleman's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile